Previously, the primary endpoint results of the NRG-LU005 study assessing the addition of the immunotherapy drug atezolizumab to standard of care concurrent chemoradiation for limited-state small cell lung cancer were reported at the American Society for Radiation Oncology 2024 Annual Meeting.
This article was originally published on MedicalXpress.com